IGHA1 and COVID-19: The SARS-CoV-2 induced cascade of events has been hypothesized to include circulating galactose deficient IgA1 (gd-IgA1) antibodies, formation of autoreactive antibodies to gd-IgA1, early conversion to IgA response, hyperactivation of IgA response in COVID-19 patients and development of immune complexes that deposit in various tissues such as skin, soft tissues, and kidneys [12].